Alpha Crest Capital Management LLC Crispr Therapeutics Ag Transaction History

Alpha Crest Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $904,585 - $1.24 Million	14,805 New	14,805 $968,000
Q1 2022 May 12, 2022	SELL	$53.19 - $79.24 $202,228 - $301,270	-3,802 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$70.09 - $111.29 $870,447 - $1.38 Million	-12,419 Reduced 76.56%	3,802 $288,000
Q3 2021 Nov 10, 2021	BUY	$110.2 - $156.64 $1.79 Million - $2.54 Million	16,221 New	16,221 $1.82 Million
Q1 2021 May 13, 2021	SELL	$110.72 - $210.04 $155,008 - $294,056	-1,400 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $111,538 - $242,522	1,400 New	1,400 $214,000

486

57.9M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.39B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.